Drug Profile
Research programme: cancer therapeutics - Alligator Bioscience
Alternative Names: ADC-1001; ADC-1001-RA; ADC-1004; ADC-1004-CHIPS; ADC-1012; ADC-1014; ADC-CHIPS; FIND-1001; FIND-1004; TNFR-SF + ND - bispecific antibody; TNFR-SF - monospecific antibodyLatest Information Update: 21 Dec 2021
Price :
$50
*
At a glance
- Originator Alligator Bioscience
- Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Bispecific antibodies; Monoclonal antibodies; Proteins
- Mechanism of Action Complement C5a inhibitors; Interleukin 1 receptor antagonists; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammation
Highest Development Phases
- No development reported Diabetes mellitus; Gout; Inflammation; Juvenile rheumatoid arthritis; Rheumatoid arthritis
- Discontinued Reperfusion injury
Most Recent Events
- 21 Dec 2021 No development reported - Preclinical for Diabetes mellitus in Sweden (SC) as of December 2021 (Alligator Bioscience pipeline, December 2021)
- 21 Dec 2021 No development reported - Preclinical for Gout in Sweden (SC) as of December 2021 (Alligator Bioscience pipeline, December 2021)
- 21 Dec 2021 No development reported - Preclinical for Inflammation in Sweden (Parenteral) as of December 2021 (Alligator Bioscience pipeline, December 2021)